Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Odonate Therapeutics	Liminal BioSciences	Hepion Pharmaceuticals	Orgenesis	GlycoMimetics
Symbol	NASDAQ:ODT	NASDAQ:LMNL	NASDAQ:HEPA	NASDAQ:ORGS	NASDAQ:GLYC
Price Information
Current Price	$2.88	$4.28	$1.59	$5.06	$2.41
52 Week Range	Hold	Hold	Buy	N/A	Buy
MarketRank™
Overall Score	1.8	1.1	1.1	0.3	1.7
Analysis Score	3.0	3.1	0.0	0.0	3.5
Community Score	2.1	1.8	2.8	0.0	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	0.0	1.7	0.0	1.7
Earnings & Valuation Score	1.3	0.6	1.3	1.3	0.6
Analyst Ratings
Consensus Recommendation	Hold	Hold	Buy	N/A	Buy
Consensus Price Target	$19.33	$18.00	$80.00	N/A	$13.00
% Upside from Price Target	571.30% upside	320.56% upside	4,931.45% upside	N/A	439.42% upside
Trade Information
Market Cap	$111.18 million	$128.16 million	$121.20 million	$123.87 million	$124.21 million
Beta	0.66	1.87	1.47	1.16	2.46
Average Volume	3,128,738	705,750	4,798,395	374,622	860,397
Sales & Book Value
Annual Revenue	N/A	$3.70 million	N/A	$33.26 million	N/A
Price / Sales	N/A	34.64	N/A	3.72	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$5.06 per share	$3.06 per share	$4.19 per share	$0.38 per share	$3.56 per share
Price / Book	N/A	1.40	N/A	13.32	N/A
Profitability
Net Income	$-111,820,000.00	$-155,020,000.00	$-6,720,000.00	$-28,220,000.00	$-57,890,000.00
EPS	($4.05)	($10.94)	($5.95)	N/A	($1.34)
Trailing P/E Ratio	N/A	N/A	N/A	1.09	N/A
Forward P/E Ratio	N/A	N/A	N/A	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-2,758.32%	N/A	600.61%	N/A
Return on Equity (ROE)	-85.75%	-196.39%	-116.73%	6.25%	-34.22%
Return on Assets (ROA)	-71.45%	-88.62%	-78.47%	3.77%	-31.43%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	2.42%	0.02%	0.12%	N/A
Current Ratio	6.68%	2.17%	3.63%	7.69%	14.83%
Quick Ratio	6.68%	1.75%	3.63%	7.68%	14.83%
Ownership Information
Institutional Ownership Percentage	96.00%	13.45%	2.97%	23.84%	82.15%
Insider Ownership Percentage	48.90%	N/A	0.10%	7.22%	26.80%
Miscellaneous
Employees	137	251	13	111	54
Shares Outstanding	38.60 million	29.94 million	76.23 million	24.48 million	51.54 million
Next Earnings Date	7/29/2021 (Estimated)	5/19/2021 (Estimated)	7/5/2021 (Estimated)	8/6/2021 (Estimated)	7/30/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Anemia Drugs Market – 2021 Predictive Analytics \|Amgen Inc, GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc – The Manomet Current - The Manomet Current manometcurrent.com - May 15 at 11:12 AM
	Is GlycoMimetics Inc (GLYC) a Leader in the Biotechnology Industry? - InvestorsObserver investorsobserver.com - May 14 at 12:29 PM
	Iron Deficiency Anemia Drug Market to Witness Rapid Growth by 2027 \| Acceleron Pharma, GlycoMimetics, Bluebird bio – Test & Measurement - Test & Measurement testmeasurement.com.au - May 14 at 1:00 AM
	2 “Strong Buy” Penny Stocks That Could See Outsized Gains - Smarter Analyst smarteranalyst.com - May 14 at 1:00 AM
	Is GlycoMimetics Inc (GLYC) a Stock to Watch After Gaining 9.57% This Week? - InvestorsObserver investorsobserver.com - May 14 at 1:00 AM
	2 “Strong Buy” Penny Stocks That Could See Outsized Gains - Yahoo Finance finance.yahoo.com - May 13 at 12:31 PM
	-$0.31 Earnings Per Share Expected for GlycoMimetics, Inc. (NASDAQ:GLYC) This Quarter americanbankingnews.com - May 12 at 5:36 PM
	Galectin 3 Market 2021: Potential growth, attractive valuation make it is a long-term investment \| Know the COVID19 Impact \| Top Players: Angion Biomedica Corp, GlycoMimetics Inc, Bristol-Myers Squibb Company, Galectin Therapeutics Inc, MandalMed Inc, etc. – Brockville Observer - Brockville Observer thebrockvilleobserver.ca - May 12 at 10:59 AM
	GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This Year - Yahoo Finance finance.yahoo.com - May 12 at 10:59 AM
	GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Might Not Expect Shareholders To Be So Generous This Year finance.yahoo.com - May 12 at 10:59 AM
	Hemoglobinopathy Treatment Drug Market 2021 Data Analysis and brief review – Bristol-Myers Squibb Company, GlycoMimetics, Pfizer, Anthera Pharmaceuticals – Clark County Blog - Clark County Blog clarkcountyblog.com - May 7 at 6:09 PM
	GlycoMimetics'(NASDAQ:GLYC) Share Price Is Down 87% Over The Past Three Years. - Yahoo Finance finance.yahoo.com - May 5 at 4:04 PM
	GlycoMimetics'(NASDAQ:GLYC) Share Price Is Down 87% Over The Past Three Years. finance.yahoo.com - May 5 at 4:04 PM
	Global CXCR4 Antagonists Market by Type (BL-8040, GMI-1359, Plerixafor (AMD3100), Balixafortide (POL6326), USL311, Others), By Application (Cancer, HIV, Chronic Inflammatory Diseases) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News Gum goodnewsgum.com - May 4 at 5:21 PM
	GlycoMimetics (NASDAQ:GLYC) Issues Quarterly Earnings Results americanbankingnews.com - May 4 at 8:35 AM
	GlycoMimetics Inc (GLYC) Q1 2021 Earnings Call Transcript - The Motley Fool fool.com - May 3 at 9:15 PM
	GlycoMimetics (NASDAQ:GLYC) Price Target Increased to $9.00 by Analysts at Stifel Nicolaus americanbankingnews.com - May 3 at 5:32 PM
	Analysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF) - Smarter Analyst smarteranalyst.com - May 3 at 4:14 PM
	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021 - Business Wire businesswire.com - May 3 at 10:18 AM
	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021 finance.yahoo.com - May 3 at 10:17 AM
	Glycobiology (Diagnostics and Therapeutics) Market 2027 COVID-19 Impact Analysis : Biomarin Pharmaceutical Inc., Glycosensors And Diagnostics Llc, Glycomimetics, Glycan Biosciences Llc, Glycotest Inc. - Clark County Blog clarkcountyblog.com - May 1 at 9:36 AM
	GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Joplin Globe joplinglobe.com - April 28 at 12:50 PM
	GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Manchestertimes manchestertimes.com - April 27 at 1:00 PM
	GlycoMimetics (GLYC) Set to Announce Quarterly Earnings on Monday americanbankingnews.com - April 27 at 10:40 AM
	GlycoMimetics to Report First Quarter Financial Results on May 3, 2021 - Yahoo Finance finance.yahoo.com - April 26 at 8:01 PM

Date	Company	Brokerage	Action
3/22/2021	Odonate Therapeutics	Lifesci Capital	Downgrade
3/22/2021	Odonate Therapeutics	The Goldman Sachs Group	Lower Price Target
3/22/2021	Odonate Therapeutics	Jefferies Financial Group	Downgrade
3/22/2021	Odonate Therapeutics	Cowen	Downgrade
9/9/2020	Odonate Therapeutics	Ci Capital	Reiterated Rating
3/26/2021	Liminal BioSciences	Leede Jones Gab	Reiterated Rating
2/25/2021	Liminal BioSciences	HC Wainwright	Initiated Coverage
1/29/2021	Liminal BioSciences	Bloom Burton	Downgrade
12/21/2020	Liminal BioSciences	Piper Sandler	Initiated Coverage
8/11/2020	Liminal BioSciences	Echelon Wealth Partners	Reiterated Rating
12/1/2020	Hepion Pharmaceuticals	Roth Capital	Boost Price Target
9/26/2019	Orgenesis	Benchmark	Initiated Coverage
12/20/2018	Orgenesis	Dawson James	Reiterated Rating
5/3/2021	GlycoMimetics	Stifel Nicolaus	Boost Price Target
11/7/2019	GlycoMimetics	Piper Jaffray Companies	Reiterated Rating
8/5/2019	GlycoMimetics	SunTrust Banks	Downgrade

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources